T1	Qualifier 25 37	uncontrolled
T2	Qualifier 13 21	unstable
T3	Qualifier 0 11	Progressive
T4	Condition 38 57	clinical conditions
*	OR T1 T2 T3
T5	Scope 0 37	Progressive, unstable or uncontrolled
R1	Has_scope Arg1:T4 Arg2:T5	
T6	Condition 60 76	Hypersensitivity
T7	Condition 88 95	allergy
T8	Drug 104 125	component of vaccines
*	OR T6 T7
T9	Drug 127 145	medicinal products
T10	Device 149 166	medical equipment
T11	Qualifier 167 202	whose use is foreseen in this study
*	OR T9 T10 T8
T12	Scope 104 166	component of vaccines, medicinal products or medical equipment
R2	Has_qualifier Arg1:T12 Arg2:T11	
T13	Scope 60 95	Hypersensitivity, including allergy
R3	Has_scope Arg1:T13 Arg2:T12	
T14	Condition 240 256	contraindication
T15	Procedure 260 285	intramuscular vaccination
T16	Procedure 290 301	blood draws
*	OR T15 T16
T17	Scope 260 301	intramuscular vaccination and blood draws
R4	Has_scope Arg1:T14 Arg2:T17	
T18	Non-representable 304 324	Clinical conditions.
T19	Qualifier 326 349	Systemic administration
T20	Drug 353 368	corticosteroids
T21	Qualifier 370 372	PO
T22	Qualifier 373 375	IV
T23	Qualifier 376 378	IM
*	OR T21 T22 T23
T24	Scope 370 378	PO/IV/IM
R5	Subsumes Arg1:T19 Arg2:T24	
R6	Has_qualifier Arg1:T20 Arg2:T19	
T25	Temporal 380 420	within 90 days prior to informed consent
T26	Reference_point 404 420	informed consent
R7	Has_index Arg1:T25 Arg2:T26	
R8	Has_temporal Arg1:T19 Arg2:T25	
T27	Drug 460 483	immunomodulating agents
T28	Drug 441 455;477 483	antineoplastic agents
*	OR T27 T28 T29
T29	Procedure 487 499	radiotherapy
T30	Temporal 500 540	within 90 days prior to informed consent
T31	Reference_point 524 540	informed consent
R9	Has_index Arg1:T30 Arg2:T31	
T32	Scope 441 499	antineoplastic and immunomodulating agents or radiotherapy
R10	Has_temporal Arg1:T32 Arg2:T30	
T33	Drug 552 567	immunoglobulins
T34	Drug 575 589	blood products
T35	Temporal 590 631	within 180 days prior to informed consent
T36	Reference_point 615 631	informed consent
R11	Has_index Arg1:T35 Arg2:T36	
*	OR T34 T33
T37	Scope 552 589	immunoglobulins or any blood products
R12	Has_temporal Arg1:T37 Arg2:T35	
T38	Qualifier 646 661	investigational
T39	Qualifier 665 679	non-registered
T40	Drug 680 697	medicinal product
T41	Temporal 698 738	within 30 days prior to informed consent
T42	Reference_point 722 738	informed consent
R13	Has_index Arg1:T41 Arg2:T42	
*	OR T39 T38
T43	Scope 646 679	investigational or non-registered
R14	Has_scope Arg1:T40 Arg2:T43	
R15	Has_temporal Arg1:T40 Arg2:T41	
T44	Non-representable 741 888	Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
T45	Drug 905 930	meningococcal vaccination
T46	Observation 894 901	history
T47	Condition 934 947;963 971	meningococcal diseases
T48	Condition 952 971	gonorrhoea diseases
*	OR T48 T47 T45
T49	Scope 905 971	meningococcal vaccination or meningococcal and gonorrhoea diseases
R16	Has_temporal Arg1:T49 Arg2:T46	
T50	Procedure 1012 1026	blood donation
T51	Non-representable 974 1011	Enrolment in any activity requiring a
T52	Multiplier 1027 1045	greater than 50 mL
R17	Has_multiplier Arg1:T50 Arg2:T52	
T53	Temporal 1046 1109	during the period starting 30 days before the first study visit
T54	Reference_point 1073 1109	30 days before the first study visit
R18	Has_index Arg1:T53 Arg2:T54	
T55	Temporal 1143 1179	for the duration of the study period
T56	Reference_point 1163 1179	the study period
R20	Has_index Arg1:T55 Arg2:T56	
*	OR T53 T55
T57	Scope 1046 1179	during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period
R19	Has_scope Arg1:T50 Arg2:T57	
T58	Drug 1212 1234	immune-modifying drugs
T59	Temporal 1235 1270	at any time during the study period
T60	Reference_point 1254 1270	the study period
R21	Has_index Arg1:T59 Arg2:T60	
R22	Has_temporal Arg1:T58 Arg2:T59	
T61	Qualifier 1200 1211	long-acting
R23	Has_qualifier Arg1:T58 Arg2:T61	
T62	Condition 1286 1301	blood disorders
T63	Observation 1320 1327	history
T64	Observation 1331 1368	difficulty in providing blood samples
R24	Has_temporal Arg1:T64 Arg2:T63	
T65	Drug 1374 1384	antibiotic
T66	Temporal 1392 1424	7 days prior to blood collection
T67	Reference_point 1408 1424	blood collection
R25	Has_index Arg1:T66 Arg2:T67	
R26	Has_temporal Arg1:T65 Arg2:T66	
T68	Procedure 1440 1447;1459 1464	donated blood
T69	Value 1448 1455	>450 mL
T70	Temporal 1465 1516	within 60 days prior to any blood collection visits
T71	Reference_point 1489 1516	any blood collection visits
R27	Has_index Arg1:T70 Arg2:T71	
R28	Has_value Arg1:T68 Arg2:T69	
R29	Has_temporal Arg1:T68 Arg2:T70	
T72	Measurement 1578 1598	lost red blood cells
T73	Value 1537 1544	>200 mL
R30	Has_value Arg1:T72 Arg2:T73	
T74	Multiplier 1554 1560	single
T75	Procedure 1561 1570	apheresis
R31	Has_multiplier Arg1:T75 Arg2:T74	
R32	AND Arg1:T75 Arg2:T72	
T76	Procedure 1632 1641	apheresis
T77	Multiplier 1602 1624	more than one occasion
T78	Temporal 1642 1669	within the previous 60 days
T79	Reference_point 1649 1669	the previous 60 days
R33	Has_index Arg1:T78 Arg2:T79	
R34	Has_multiplier Arg1:T76 Arg2:T77	
R35	Has_temporal Arg1:T76 Arg2:T78	
*	OR T75 T76
T80	Temporal 1672 1684	Concurrently
T81	Observation 1685 1701;1710 1724	participating in clinical study
R36	Has_temporal Arg1:T81 Arg2:T80	
T82	Temporal 1726 1761	at any time during the study period
R37	Has_temporal Arg1:T81 Arg2:T82	
T83	Reference_point 1745 1761	the study period
R38	Has_index Arg1:T82 Arg2:T83	
T84	Drug 1859 1866	vaccine
T85	Drug 1867 1874	product
*	OR T84 T85
T86	Scope 1859 1874	vaccine/product
T87	Qualifier 1818 1833	investigational
T88	Qualifier 1839 1858	non-investigational
*	OR T87 T88
T89	Scope 1818 1858	investigational or a non-investigational
R39	Has_scope Arg1:T86 Arg2:T89	
R40	Has_scope Arg1:T81 Arg2:T86	
T90	Temporal 1876 1883	Ongoing
T91	Condition 1884 1891	anaemia
R41	Has_temporal Arg1:T91 Arg2:T90	
T92	Measurement 1908 1919	haemoglobin
T93	Value 1927 1992	below the lower limit of the laboratory-specified reference range
R42	Has_value Arg1:T92 Arg2:T93	
R43	AND Arg1:T91 Arg2:T92	
T94	Procedure 2001 2020	finger prick method
T95	Condition 2037 2044	anaemia
R44	AND Arg1:T94 Arg2:T95	
*	OR T91 T94
T96	Non-representable 2096 2273	and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anaemia has been resolved.
T97	Condition 2290 2298	reaction
T98	Condition 2302 2318	hypersensitivity
T99	Qualifier 2319 2376	likely to be exacerbated by any component of the vaccines
T100	Drug 2351 2376	component of the vaccines
R45	multi Arg1:T99 Arg2:T100	
*	OR T97 T98
T101	Scope 2290 2318	reaction or hypersensitivity
R46	Has_qualifier Arg1:T101 Arg2:T99	
T102	Condition 2379 2387	Pregnant
T103	Observation 2391 2400	lactating
T104	Person 2401 2407	female
*	OR T102 T103
T105	Person 2410 2416	Female
T106	Observation 2417 2444	planning to become pregnant
T107	Mood 2448 2471	planning to discontinue
T108	Observation 2472 2497	contraceptive precautions
R47	Has_mood Arg1:T108 Arg2:T107	
*	OR T106 T108
T109	Mood 2417 2428	planning to
T110	Observation 2429 2444	become pregnant
R48	multi Arg1:T106 Arg2:T110	
R49	Has_mood Arg1:T110 Arg2:T109	
T111	Qualifier 2504 2513	confirmed
T112	Mood 2517 2526	suspected
T113	Condition 2527 2544;2565 2574	immunosuppressive condition
T114	Condition 2548 2574	immunodeficiency condition
*	OR T114 T113
T115	Observation 2584 2599	medical history
T116	Procedure 2604 2624	physical examination
*	OR T115 T116
T117	Scope 2584 2624	medical history and physical examination
T118	Scope 2527 2574	immunosuppressive or immunodeficiency condition
*	OR T111 T112
T119	Scope 2504 2526	confirmed or suspected
R50	Has_scope Arg1:T118 Arg2:T119	
R51	Has_scope Arg1:T118 Arg2:T117	
T120	Observation 2626 2640	Family history
T121	Condition 2658 2685	hereditary immunodeficiency
T122	Condition 2644 2654;2669 2685	congenital immunodeficiency
*	OR T121 T122
T123	Scope 2644 2685	congenital or hereditary immunodeficiency
R52	Has_context Arg1:T123 Arg2:T120	
T124	Qualifier 2688 2695	Serious
T125	Condition 2696 2711	chronic illness
R53	Has_qualifier Arg1:T125 Arg2:T124	
T126	Condition 2725 2752	chronic alcohol consumption
T127	Condition 2760 2770	drug abuse
*	OR T126 T127
T128	Observation 2714 2721	History
T129	Scope 2725 2770	chronic alcohol consumption and/or drug abuse
R54	Has_temporal Arg1:T129 Arg2:T128	
